Please ensure Javascript is enabled for purposes of website accessibility
Alzheimer's Drug Shows Promise in Early Results of Study
gvw_ap_news
By Associated Press
Published 3 years ago on
September 28, 2022

Share

 

Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease in a late-stage study.

The drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18 months of the infused treatment.

Eisai announced results late Tuesday from a global study of nearly 1,800 people with early-stage Alzheimer’s.

Patients were monitored using a scale that measures mental decline and their ability to do daily activities like getting dressed or feeding oneself.

Eisai Co. Ltd. said it would discuss full results from the research at a conference in late November. It also plans to publish findings in a peer-reviewed medical journal.

The company is already seeking an accelerated approval from the U.S. Food and Drug Administration, and the agency is expected to decide by early next year. Eisai and Biogen will co-promote the drug.

Researchers typically urge caution in evaluating a study until the full results are released. But the initial findings appear to be “quite robust” and will likely support regulatory approval, Mizuho Securities analyst Graig Suvannavejh said in a research note.

A statement from the Alzheimer’s Association called the findings the most encouraging to date for potential treatments of the underlying disease causes.

Some 6 million people in the U.S. and many more worldwide have Alzheimer’s, which gradually attacks areas of the brain needed for memory, reasoning, communication and basic daily tasks.

Alzheimer’s has no known cure. Long-standing treatments on the market just manage symptoms, and researchers don’t fully understand what causes the disease.

Last year, Biogen’s Aduhelm became the first new Alzheimer’s drug introduced in nearly two decades. But it has largely flopped after debuting with a price tag of $56,000 annually, which Biogen later slashed.

Doctors have been hesitant to prescribe it, given weak evidence that the drug slows the progression of Alzheimer’s. Insurers have blocked or restricted coverage due to concerns over the drug’s high price tag and uncertain benefit.

Earlier this year, the federal Medicare program imposed strict limits on who can get the drug, wiping out most of its potential U.S. market. Biogen announced afterward that it would stop most of its spending on the treatment.

Like Aduhelm, lecanemab, which Eisai developed, aims to clear a protein called beta-amyloid from the brain.

The protein forms a plaque that researchers believe is a contributor to Alzheimer’s. They also point to other potential factors like family history and chronic conditions such as diabetes.

Eisai executives say lecanemab focuses more on floating clumps of the protein before it forms the plaque, which is what Aduhelm targets.

Eli Lilly and Co. also is developing a potential treatment, donanemab, that targets the protein.

Shares of Cambridge, Massachusetts-based Biogen Inc. jumped 35% to $267.29 in Wednesday morning trading as the broader indexes edged higher. The stock had largely tumbled since Aduhelm’s debut last year.

Shares of Indianapolis-based Eli Lilly and Co. were up more than 8%.

RELATED TOPICS:

DON'T MISS

What Are Fresno Real Estate Experts Predicting for 2025 and Beyond?

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

World’s Largest Almond Processor Will Shutter Sacramento Plant. 600 Workers Impacted

DON'T MISS

Trump Eyes Major Funding Cuts for California, Including All Public Universities

DON'T MISS

Farming Regulation Costs Rise 1,300% Since 2006: Cal Poly

DON'T MISS

Southern California Air Regulators Weigh a Plan to Phase Out Gas Furnaces and Water Heaters

DON'T MISS

US Supreme Court Allows DOGE Broad Access to Social Security Data

DON'T MISS

Doctors Were Preparing to Remove Their Organs. Then They Woke Up.

DON'T MISS

Abrego Garcia Is Returned to US From El Salvador

DON'T MISS

Proud Boys Convicted in Jan. 6 Attack Sue Government on Claims of ‘Political Persecution’

DON'T MISS

FDA’s AI Assistant ‘Elsa’ Fails Its First Day on the Job

DON'T MISS

Documentary Series Goes Inside Trump’s Bubble

UP NEXT

Documentary Series Goes Inside Trump’s Bubble

UP NEXT

Whooping Cough Is Surging. Do You Need Another Shot?

UP NEXT

8 Ways Musk and Trump Could Inflict Pain on Each Other

UP NEXT

How Trump’s Pick for Surgeon General Uses Her Big Online Following to Make Money

UP NEXT

16 Palestinians Killed in Israeli Strikes on Gaza, Health Officials Say

UP NEXT

Three Killed, 49 Wounded in Intense Russian Air Attacks on Ukraine

UP NEXT

Trump Administration Imposes Sanctions on Four ICC Judges in Unprecedented Move

UP NEXT

SpaceX Will Decommission Dragon Spacecraft, Musk Says as Feud With Trump Escalates

UP NEXT

Israeli Military Strikes Beirut’s Southern Suburbs

UP NEXT

Millions Would Lose Their Obamacare Coverage Under Trump’s Bill

Southern California Air Regulators Weigh a Plan to Phase Out Gas Furnaces and Water Heaters

2 hours ago

US Supreme Court Allows DOGE Broad Access to Social Security Data

2 hours ago

Doctors Were Preparing to Remove Their Organs. Then They Woke Up.

2 hours ago

Abrego Garcia Is Returned to US From El Salvador

2 hours ago

Proud Boys Convicted in Jan. 6 Attack Sue Government on Claims of ‘Political Persecution’

3 hours ago

FDA’s AI Assistant ‘Elsa’ Fails Its First Day on the Job

3 hours ago

Documentary Series Goes Inside Trump’s Bubble

3 hours ago

Tulare County Gang Member Convicted of Trying to a Murder Police Officer

3 hours ago

Newsom Promises Funding to Jump-Start ‘Science of Reading’

4 hours ago

Feds Indict SoCal Hospice CEO for Medicare Fraud in Fresno and Kern Counties

4 hours ago

World’s Largest Almond Processor Will Shutter Sacramento Plant. 600 Workers Impacted

The world’s largest almond processor, Blue Diamond Growers, says it will close its Sacramento processing plant this year The almond co...

28 minutes ago

28 minutes ago

World’s Largest Almond Processor Will Shutter Sacramento Plant. 600 Workers Impacted

2 hours ago

Trump Eyes Major Funding Cuts for California, Including All Public Universities

2 hours ago

Farming Regulation Costs Rise 1,300% Since 2006: Cal Poly

3 hours ago

Southern California Air Regulators Weigh a Plan to Phase Out Gas Furnaces and Water Heaters

3 hours ago

US Supreme Court Allows DOGE Broad Access to Social Security Data

3 hours ago

Doctors Were Preparing to Remove Their Organs. Then They Woke Up.

3 hours ago

Abrego Garcia Is Returned to US From El Salvador

4 hours ago

Proud Boys Convicted in Jan. 6 Attack Sue Government on Claims of ‘Political Persecution’

Help continue the work that gets you the news that matters most.

Search

Send this to a friend